Dr Da-Yong LU, born in July, 1962 in Shanghai. oc/professor; ed/ph D Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 2005, MS, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 1986, BS, Shanghai Medical University (Now Fudan University affiliated) in1982; He is working as an associated professor at Shanghai University, Shanghai200444, PR China. Undergo the studies of cancer pathology, biochemistry, pharmacology and clinical therapeutics, especially on the pharmacological studies of new Chinese anticancer agent probimane and MST-16 and antimetastatic targets of fibrinogen, calmodulin, sialic acids, individualized cancer chemotherapy (ICC) in clinics and so on since 1982. His interest is focused on the basic studies of cancer biology, pathology, treatment, origins of life and other field of scientific disciplines. He is serving as an editorial member of several reputed international journals. He was the first author of more than 90 original scientific articles published in international journals and two books on cancer clinical therapeutics (Personalized Cancer Chemotherapy, Elsevier, 2014) and human suicide prediction/therapeutics (Suicide Risks & Therapeutics, New Ideas & Future Perspectives, Nova Scientific Publishers, UK, 2017).
Apart from cancer pathogenesis, pharmacology and therapeutics studies, he is also interested on the studies of viral infection therapeutic study on the fields of HIV/AIDS studies in more than 10 international journal articles.